Details

Autor(en) / Beteiligte

• Chevallier, P
• Labopin, M
• Turlure, P
• Prebet, T
• Pigneux, A
• Hunault, M
• Filanovsky, K
• Cornillet-Lefebvre, P
• Luquet, I
• Lode, L
• Richebourg, S
• Blanchet, O
• Gachard, N
• Vey, N
• Ifrah, N
• Milpied, N
• Harousseau, J.-L
• Bene, M.-C
• Mohty, M
• Delaunay, J

Titel

A new leukemia prognostic scoring system for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study

Ist Teil von

• Leukemia, 2011-06, Vol.25 (6), p.939

Ort / Verlag

Nature Publishing Group

Erscheinungsjahr

2011

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• A simplified prognostic score is presented based on the multivariate analysis of 138 refractory/relapsed acute myeloid leukaemia (AML) patients (median age 55 years, range: 19-70) receiving a combination of intensive chemotherapy l Gemtuzumab as salvage regimen. Overall, 2-year event-free survival (EFS) and overall survival (OS) were 29 ± 4% and 36 ± 4%, respectively. Disease status (relapse -12 months, including refractory patients), FLT3-ITD-positive status and high-risk cytogenetics were the three strongest independent adverse prognostic factors for OS and EFS in this series. We then defined three subgroups with striking different outcomes at 2 years: no adverse factor (favourable, N = 36): OS 58%, EFS 45%; one adverse factor (intermediate, N = 54): OS 37%, EFS 31%; two or three adverse factors (poor, N = 43): OS 12%, EFS 12% (P < [10.sup.-4], P = 0.001). This new simplified Leukemia Prognostic Scoring System was then validated on an independent cohort of 111 refractory/relapsed AML patients. This new simplified prognostic score, using three clinical and biological parameters routinely applied, allow to discriminate around two third of the patients who should benefit from a salvage intensive regimen in the setting of refractory/relapsed AML patients. The other one third of the patients should receive investigational therapy. Leukemia (2011) 25, 939-944; doi: 10.1038/leu.2011.25; published online 18 February 2011 Keywords: AML; refractory; relapse; score; NPM1; FLT3